Welcome to our dedicated page for INNOVATIVE EYEWEAR SEC filings (Ticker: LUCYW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innovative Eyewear, Inc. Series A Warrants (LUCYW) SEC filings page centralizes access to the company’s regulatory disclosures related to both its common stock (LUCY) and its exchange‑listed warrants. Innovative Eyewear files reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934, and these documents provide detailed information on its smart eyewear business, capital structure, governance and warrant activity.
Key filings include current reports on Form 8‑K, which disclose material events such as inducement letter agreements with existing warrant holders, the issuance of new warrant series, and changes to at‑the‑market offering programs. For example, recent 8‑K filings describe agreements under which holders exercised existing warrants for cash in exchange for new Series I warrants, outline the terms of placement agent warrants, and specify that both the common stock and warrants are listed on The Nasdaq Stock Market LLC under the symbols LUCY and LUCYW.
Definitive proxy statements on Schedule 14A (DEF 14A) provide insight into governance matters, including director elections, auditor ratification, rights plan amendments and proposals to amend the Articles of Incorporation to change the company’s name to Lucyd, Inc. These proxy materials also explain how shareholders can vote at the annual meeting and identify which securities are entitled to vote.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q, referenced in the proxy materials, contain audited and interim financial statements, risk factors and management’s discussion of the smart eyewear operations that underpin the value of LUCY common stock and LUCYW warrants. Together with Form 4 insider transaction reports and registration statements covering warrant exercises and resale arrangements, these filings allow investors to track equity issuance, warrant terms, and other capital markets activities.
On Stock Titan, each new Innovative Eyewear filing is surfaced shortly after it appears in the SEC’s EDGAR system. AI‑generated summaries help explain the purpose and main points of complex documents, such as warrant inducement agreements, at‑the‑market prospectus supplements, and proxy proposals, so that readers can quickly understand how a filing may relate to LUCY shares or LUCYW warrants without reading every page.
Innovative Eyewear Inc. received a new large shareholder disclosure from individual investor Kelly Joseph Chapman. As of the event date, Chapman reported beneficial ownership of 343,023 shares of Innovative Eyewear common stock, representing 6.41% of the class. The filing states that Chapman has sole power to vote and dispose of all 343,023 shares, with no shared voting or dispositive power.
The Schedule 13G identifies Chapman as a U.S. individual investor, not part of any group and not acting through subsidiaries. Chapman certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Innovative Eyewear, and are not held in connection with any control-related transaction other than activities solely in connection with a nomination under the specified proxy rule.
Innovative Eyewear Inc. insider activity: Chief Executive Officer and director Harrison R. Gross reported buying 1,500 shares of Innovative Eyewear common stock on January 21, 2026 at a price of $1.32 per share. Following this purchase, he directly beneficially owns 13,733 common shares.
The filing notes that this transaction created a short-swing profit under Section 16(b) of the Securities Exchange Act of 1934. Gross agreed to voluntarily disgorge $1,036.20, described as the full amount of that profit, to Innovative Eyewear, and this amount was paid in full on January 21, 2026.
Form 144 notice for Innovative Eyewear, Inc. (ticker LUCYW) discloses a proposed sale of 760 common shares through Raymond James on 09/10/2025 on the NASDAQ with an aggregate market value of $1,611.20. The securities were acquired as an RSU grant on 08/19/2025 totaling 7,200 shares with payment in cash recorded on the same date. The filing also lists a prior sale by the reporting person of 2,225 shares on 08/19/2025 generating $4,422.00 in gross proceeds. The notice includes the standard representation that the seller does not possess undisclosed material information.
Innovative Eyewear, Inc. (ticker: LUCYW) Form 144 notice reports a proposed sale of 2,596 common shares valued at an aggregate $5,057.55 to be sold through Raymond James & Associates on 08/19/2025 on NASDAQ. The filer shows the shares were acquired the same day, 08/19/2025, as an RSU grant from the issuer representing 8,400 shares granted, with the reported form indicating cash payment. The filing lists total shares outstanding as 4,574,602. No securities were reported sold by the filer in the prior three months and no additional remarks or plan-adoption dates are provided.
Form 144 notice: A person affiliated with Innovative Eyewear, Inc. (ticker LUCYW) notified a proposed sale of 1,485 common shares08/19/2025. The filing lists an aggregate market value of $2,889.95 for the shares and reports 4,574,602 shares outstanding. The securities were acquired the same day as an RSU grant dated 08/19/2025 for 4,800 shares, with cash listed as the payment method. The filer attests they are not aware of any undisclosed material adverse information about the issuer.
Innovative Eyewear, Inc. (LUCYW) Form 144 reports a proposed sale of 3,009 common shares to be executed through Raymond James & Associates on 08/19/2025 on NASDAQ. The filing lists an aggregate market value of $5,894.17 for the shares and states total shares outstanding of 4,574,602, providing the basic size and timing of the planned transaction.
The securities were acquired as an RSU grant on 08/19/2025 (noted amount: 9,600 shares) with cash listed as the payment type. The filer attests by signature that they do not possess undisclosed material adverse information about the issuer.
Form 144 notice for Innovative Eyewear, Inc. (symbol LUCYW) reports a proposed sale of 2,225 common shares through Raymond James on 08/19/2025 with an aggregate market value of $4,421.80. The filing shows the securities were acquired the same day as an RSU grant (8,200 units granted; 7,200 units listed as acquired) and payment is listed as cash. The issuer's outstanding shares are stated as 4,574,602. Several standard filer and issuer contact fields are blank in the submission.
Form 144 notice for Innovative Eyewear, Inc. (ticker LUCYW) shows a proposed sale of 1,670 common shares through Raymond James on 08/19/2025 on NASDAQ with an aggregate market value of $3,317.35. The filing reports the securities were acquired as an RSU grant from the issuer on 08/19/2025, with 5,400 units acquired and payment marked as cash. The issuer’s total shares outstanding are listed as 4,574,602. The filer certifies they are not aware of undisclosed material adverse information and indicates no securities sold in the prior three months.
Innovative Eyewear, Inc. reported that on August 15, 2025 it filed a prospectus supplement to increase the maximum number of shares of its common stock that may be issued under its existing At The Market Offering Agreement with H.C. Wainwright & Co., originally dated April 15, 2024. This update means the company can issue more common shares through that ongoing at-the-market program as needed, rather than in a single large transaction.
The company also filed a legal opinion from Ellenoff Grossman & Schole LLP, attached as Exhibit 5.1, confirming the legality of issuing and selling these shares. A related consent from the same firm is included as Exhibit 23.1.
The company is updating its at-the-market common stock offering to allow sales of up to $2,679,217 of common stock through H.C. Wainwright & Co. under an existing sales agreement and shelf registration. This amount excludes approximately $1,202,269 of common stock already sold under earlier related prospectus supplements. The filing notes a public float of about $11,644,460, based on 3,298,714 shares held by non-affiliates at $3.53 per share as of June 20, 2025. The common stock trades on the Nasdaq Capital Market under the symbol LUCY, with a last reported price of $2.20 per share on August 14, 2025. Investors are directed to detailed risk factor discussions before purchasing shares.